



\$1,427.00 **PATENT APPLICATION**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: A8427

Mary G. HOFFEE et al

Appln. No.: 10/700,632

Group Art Unit: 1643

Confirmation No.: 8127

Examiner: Blanchard, D.

Filed: November 5, 2003

For: **ANTI-CD33 ANTIBODIES AND METHODS FOR TREATMENT OF ACUTE
MYELOID LEUKEMIA USING THE SAME**

DECLARATION UNDER 37 C.F.R. § 1.132

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

We, Mary G. Hoffee, Daniel Tavares and Robert J. Lutz, hereby declare and state:

THAT we are each citizens of the United States;

THAT we are joint inventors of the invention disclosed and claimed in the above
identified patent application; and


THAT the **R&D Focus Drug News** item dated **November 12, 2001**, discloses
information derived from one or more of us. In particular, the monoclonal antibody My9-6
referred to in the item is the work of one or more of us.

We declare further that all statements made herein of our own knowledge are true and
that all statements made on information and belief are believed to be true; and further that these
statements were made with the knowledge that willful false statements and the like so made are
punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States
Code, and that such willful false statements may jeopardize the validity of the application or any
patent issuing thereon.


DECLARATION UNDER 37 C.F.R. § 1.132
Appln. No.: 10/700,632

A8427


Date: Nov 9, 2006


Mary G. Hoffee

Date: November 3, 2006


Daniel Tavares

Date: November 3, 2006


Robert J. Lutz



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: A8427

Mary G. HOFFEE et al

Appln. No.: 10/700,632

Group Art Unit: 1643

Confirmation No.: 8127

Examiner: Blanchard, D.

Filed: November 5, 2003

For: ANTI-CD33 ANTIBODIES AND METHODS FOR TREATMENT OF ACUTE
MYELOID LEUKEMIA USING THE SAME

DECLARATION UNDER 37 C.F.R. § 1.132

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

We, Mary G. Hoffee, Daniel Tavares and Robert J. Lutz, hereby declare and state:

THAT we are each citizens of the United States;

THAT we are joint inventors of the invention disclosed and claimed in the above
identified patent application; and

THAT one or more of us is a co-author of **Goldmacher et al., Abstract #1265 of the
Proceedings of the American Association for Cancer Research 43:254 (2002).**


We further declare and state as follows:

THAT even though Victor Goldmacher, Barbara Leece, Laura Bartle, Cheryl Dionne,
Rita Steeves and Ravi V.J. Chari are co-authors of the Abstract, they are not co-inventors of the
invention disclosed and claimed in the above-identified application. Rather, to the extent the
work of Victor Goldmacher, Barbara Leece, Laura Bartle, Cheryl Dionne, Rita Steeves and Ravi
V.J. Chari relates to the My9-6 antibody, each of these co-authors were working under the
direction of one or more of us. Thus, Victor Goldmacher, Barbara Leece, Laura Bartle, Cheryl


Dionne, Rita Steeves and Ravi V.J. Chari had no role in the conception of the invention described and claimed in the above-identified patent application.

We declare further that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.


Date: November 9, 2006


Mary G. Hoffee

Date: November 3, 2006


Daniel Tavares

Date: November 3, 2006


Robert J. Lutz



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: A8427

Mary G. HOFFEE et al

Appln. No.: 10/700,632

Group Art Unit: 1643

Confirmation No.: 8127

Examiner: Blanchard, D.

Filed: November 5, 2003

For: ANTI-CD33 ANTIBODIES AND METHODS FOR TREATMENT OF ACUTE
MYELOID LEUKEMIA USING THE SAME

DECLARATION UNDER 37 C.F.R. § 1.132

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

We, Mary G. Hoffee, Daniel Tavares and Robert J. Lutz, hereby declare and state:

THAT we are each citizens of the United States;

THAT we are joint inventors of the invention disclosed and claimed in the above
identified patent application; and

THAT one or more of us is a co-author of **Lutz et al., Abstract #4518 of the
Proceedings of the American Association for Cancer Research 43:912 (2002).**

We further declare and state as follows:

THAT even though Hongsheng Xie, Cheryl Dionne, Rita Steeves, Victor Goldmacher, Barbara Leece, Laura Bartle and Ravi Chari are co-authors of the Abstract, they are not co-inventors of the invention disclosed and claimed in the above-identified application. Rather, to the extent the work of Hongsheng Xie, Cheryl Dionne, Rita Steeves, Victor Goldmacher, Barbara Leece, Laura Bartle and Ravi Chari relates to the My9-6 antibody, each of these co-authors were working under the direction of one or more of us. Thus, Hongsheng Xie, Cheryl Dionne, Rita Steeves, Victor Goldmacher, Barbara Leece, Laura Bartle and Ravi Chari had no


DECLARATION UNDER 37 C.F.R. § 1.132
Appln. No.: 10/700,632

A8427


role in the conception of the invention described and claimed in the above-identified patent application.

We declare further that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.


Date: November 9, 2006


Mary G. Hoffee

Date: November 3, 2006


Daniel Tavares

Date: November 3, 2006


Robert J. Lutz